Candel Therapeutics, Inc.
CADL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CADL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CADL
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for cancer, with lead candidates aglatimagene (CAN-2409) and linoserpaturev (CAN-3110) in clinical trials.
Key risk: No product revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.00B
Cash Runway
35.4 moLead Asset
aglatimagene besadenovec (Phase 3)Next Catalyst
Phase3_Topline · Oct 22, 2031Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials · 1 catalyst for Candel Therapeutics, Inc..
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for cancer, with lead candidates aglatimagene (CAN-2409) and linoserpaturev (CAN-3110) in clinical trials.
- Candel has not generated any revenue from product sales and has incurred significant operating losses since inception [sec_mda · as of 2026-08-13].
- As of June 30, 2026, Candel reported cash and equivalents of $202.0M, net loss of -$38.9M, shareholders' equity of $51.9M, and total debt of $46.7M [sec].
- The company expects operating expenses to increase substantially as it advances aglatimagene and linoserpaturev through clinical development and manufacturing scale-up [sec_mda · as of 2026-05-14].
- Candel's lead candidate aglatimagene is being evaluated in a Phase 3 trial for non-small cell lung cancer (NSCLC), with topline data expected around October 22, 2031 [catalyst].
- The company has a loan and security agreement providing additional capital, with prior cash runway guidance extending into Q1 2027 [sec_mda · as of 2025-11-13].
What works
- Candel has a robust cash position of $202.0M as of June 30, 2026, providing a multi-year runway to advance key clinical programs [sec].
- The company's lead candidate aglatimagene is in a pivotal Phase 3 trial for NSCLC, a large market opportunity, with a defined catalyst date [catalyst].
- Candel's platform of off-the-shelf viral immunotherapies (aglatimagene and linoserpaturev) targets multiple solid tumor indications, diversifying pipeline risk [sec_mda · as of 2026-03-12].
What to weigh
- Candel has no approved products and has never generated revenue from product sales, relying entirely on external financing [sec_mda · as of 2026-08-13].
- The company expects operating expenses to increase significantly, which will pressure cash reserves and may require additional capital before reaching profitability [sec_mda · as of 2026-05-14].
- The Phase 3 topline readout for aglatimagene is not expected until late 2031, implying a long development timeline with no near-term revenue catalysts [catalyst].
From the filings
Quoted directly from source documents.
Candel has not generated any product revenue and has significant operating losses.
“Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses.”
SEC MD&A · August 13, 2026
Candel expects operating expenses to increase substantially as it advances its pipeline.
“We expect our operating expenses to increase substantially in the future in connection with our ongoing activities, particularly as we advance aglatimagene and linoserpaturev through research and development, clinical trials, and develop our manufacturing capabilities”
SEC MD&A · May 14, 2026
Catalyst timeline
- 2031-10-22 · Phase3_Topline · aglatimagene — Topline data from the Phase 3 trial of aglatimagene besadenove in non-small cell lung cancer will be a key value inflection point.
Risks & what to watch (4)›
Key risks
- No product revenue — Candel has never generated revenue from product sales and relies on external financing to fund operations [sec_mda · as of 2026-08-13].
- Long development timeline — Phase 3 topline data for aglatimagene is not expected until late 2031, with no near-term catalysts [catalyst].
- Increasing operating costs — Expenses are expected to rise substantially as the company advances clinical trials and manufacturing [sec_mda · as of 2026-05-14].
- Dependence on single candidate — Aglatimagene is the most advanced candidate; failure in Phase 3 would significantly impact the company [sec_mda · as of 2026-03-12].
What to watch
- Phase 3 topline data for aglatimagene in NSCLC, expected around October 22, 2031 [catalyst].
- Updates on the clinical development of linoserpaturev (CAN-3110) in recurrent high-grade glioma [sec_mda · as of 2025-11-13].
- Cash runway and potential need for additional financing as operating expenses increase [sec_mda · as of 2026-05-14].
- Regulatory milestones or partnership announcements that could accelerate development or provide non-dilutive capital [sec_mda · as of 2025-11-13].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Candel Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Candel Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
35.4 months
D/E 0.65 · 0% dilution
Lead: Phase 3
4 candidates
1 upcoming, next in ~1879d
0 buys · 3 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
112
Total value held
$194.8M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 10,987,017 | $53.8M |
| rtw investments, lp | 6,422,018 | $31.5M |
| vanguard capital management llc | 4,925,514 | $24.1M |
| acorn capital advisors, llc | 3,497,948 | $17.2M |
| blackrock, inc. | 3,109,042 | $15.2M |
| millennium management llc | 1,060,086 | $5.2M |
| geode capital management, llc | 1,035,435 | $5.1M |
| halter ferguson financial inc. | 904,051 | $4.4M |
| state street corp | 818,558 | $4.0M |
| heights capital management, inc | 775,000 | $3.8M |
Showing top 10 of 112 institutional holders of Candel Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 26.1%
- Days to cover
- 8.9
- Shares short
- 14,681,430
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CADL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Candel Therapeutics, Inc.?
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies for cancer, with lead candidates aglatimagene (CAN-2409) and linoserpaturev (CAN-3110) in clinical trials.
What is Candel Therapeutics, Inc.'s lead drug candidate?
Candel Therapeutics, Inc.'s most advanced tracked candidate is aglatimagene besadenovec (Phase 3) for Non-squamous, Non-Small Cell Lung Cancer; Non Small Cell Lung Cancer.
What is Candel Therapeutics, Inc.'s next catalyst?
Candel Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenove" — expected October 22, 2031.
Who is the CEO of Candel Therapeutics, Inc.?
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. is the chief executive officer of Candel Therapeutics, Inc. (CADL).
Where is Candel Therapeutics, Inc. headquartered?
Candel Therapeutics, Inc. (CADL) is headquartered in Needham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.